Where the wall will fall first.

Most believe that 'generic' biologics are not a question of if, but when. Just when, though, and which therapies could face a threat in the marketplace, depend on the complexity of the product. Research is far along, indicating that some of today's biggest markets could be exposed when the wall comes tumbling down.